Clinicopathological studies have demonstrated that Alzheimer's disease dementia (ADD) is often accompanied by clinically undetectable comorbid neurodegenerative and cerebrovascular disease that alter the presence and rate of cognitive decline in aging and ADD. Aside from causing increased variability in clinical response, it is possible that the major ADD comorbidities may not respond to ADD-specific molecular therapeutics. As most reports have focused on comorbidity in the oldest-old, its extent in younger age groups that are more likely to be involved in clinical trials is largely unknown. We conducted a survey of neuropathological comorbidities in sporadic ADD using data from the US National Alzheimer's Coordinating Center. Subject data was restricted to those with dementia and meeting National Institute on Aging-Alzheimer's Association (NIA-AA) intermediate or high AD Neuropathological Change (ADNC) levels, excluding those with known autosomal dominant AD-related mutations. Subjects were divided into age-atdeath categories for analysis: under 60, 60-69, 70-79, 80-89, 90-99 and 100 or over. Confirmatory of earlier reports, ADD histopathology is less severe with advancing age, effectively increasing the relative contribution of comorbidities, most of which rise in prevalence with age. Highly prevalent ADD comorbidities are not restricted to the oldest-old but are common even in early-onset ADD. The percentage of cases with ADD as the sole major neuropathological diagnosis is highest in the under-60 group, where "pure" ADD cases are still in the minority at 44%. After this AD as a sole major pathology in ADD declines to roughly 20% in the 70s and beyond. Comorbidity rates for some pathologies, especially LBD, are high even in subjects in their 60s and 70s, at nearly 60%, but for most others, their prevalence increases with age. TDP-43 pathology affects more than 35% of ADD subjects 80 and over while microscopic infarcts reach this rate a decade later. Gross infarcts rise more slowly and affect fewer subjects but still involve 15-20% of ADD after age 80. White matter rarefaction may be underestimated in the NACC database but is present in almost 70% of centenarians with ADD. Effective clinical trials depend on accurate estimates of required subject numbers, which are dependent on observed effect size and clinical response variability. Comorbidities are likely to affect both, leading to lower probability of clinical trial success. Stratifying ADD clinical trial analyses by presence and types of accompanying comorbidities might identify subgroups with higher effect sizes and greater clinical response rates, but accurate in-vivo diagnostic methods for most comorbidities are still lacking. Neuropathological studies are increasingly demonstrating that Alzheimer's disease dementia (ADD) is most often not the sole brain pathology in those that die and are autopsied, but is very likely to be accompanied by comorbid neurodegenerative and cerebrovascular disease. Comorbidities are likely to alter the presence and rate of cognitive decline in aging and ADD . If all neuropathological changes found in elderly brains were considered, there would be few if any cases of "pure" ADD. While not all of these aging changes are likely be clinically significant [37] , several of the commonly-observed ADD comorbidities have been demonstrated to contribute to cognitive impairment, including Lewy body disease (LBD) [4, 23, 26, 30, [41] [42] [43] [44] [45] [46] [47] , hippocampal sclerosis [29, [47] [48] [49] [50] [51] [52] , 13, 37, [53] [54] [55] [56] [57] and cerebral infarcts [1, 10, 11, 30, 35, 46, 57, 58, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] . Aside from causing increased variability in clinical response, it is possible that these major comorbidities, each of which is individually capable of causing dementia, may not respond to ADD-specific molecular therapeutics because their molecular pathogenesis is different from ADD. At present, there are no accurate methods available with which to clinically diagnose these complications of ADD.
Introduction
Cerebrovascular disease, as a whole, may be of equal or greater importance as an ADD comorbidity, as compared to LBD and TDP-43. Microscopic infarcts rise steadily in prevalence with age, at 40-50% becoming the most common ADD comorbidity after age 90. Gross infarcts rise more slowly and affect fewer subjects but still involve 15-20% of ADD after age 80. Both of these infarct classes have been reported to be independent influences on cognition [1, 10, 11, 30, 35, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] . White matter rarefaction (WMR) has long been reported to be roughly twice as common in ADD as compared to normal elderly, being present in 60% or more of ADD subjects [121] [122] [123] . At 30-70%, the NACC database may be underestimating WMR. This may be due to the difficulty of detecting it with only standard small-block histology sampling. Without setting thresholds of severity, MRI-detected WMR has been reported to be present in 39-96% of elderly subjects and close to 100% of those with ADD [124] . Correlations of WMR with cognition have been complicated by co-linearity with AD histopathology as well as a dual vascular and AD-related pathogenesis [58, 70, [125] [126] [127] [128] [129] [130] [131] [132] , but when WMR rarefaction in ADD is severe, or in non-demented older subjects where AD histopathology is minimal, there are significant associations, especially with frontal lobe functions or longitudinal decline [124, [133] [134] [135] [136] . Like LBD, WMR is highly prevalent in autosomal dominant early-onset AD and thus is probably at least partially dependent on AD-related factors [137] [138] [139] .
In the NACC database, microhemorrhages are much less common than infarcts and WMR, reaching only 5-8% prevalence after age 80. Again these may be underestimated at autopsy as compared to MRI, or when special efforts are made in postmortem examination, as one autopsy center has reported a prevalence rate of 62% in oldest-old subjects [140] . In the Alzheimer's Disease Neuroimaging Initiative, 25% of a mixed group of subjects, with normal cognition, mild cognitive impairment, and ADD, had microhemorrhages, with a tendency for proportionately more in AD [141] . Microhemorrhages are reported to increase risk for incident dementia [142] .
Non-AD tauopathies, with microscopic tau pathologist that is morphologically unlike the neurofibrillary tangles of AD, are relatively uncommon ADD comorbidities in the NACC database, being present in under 10% or less of subjects under 90. It is possible that these tauopathies may often be overlooked against the background of severe AD neurofibrillary pathology. Reports from centers that specifically look for argyrophilic grains and aging-related tau astrogliopathy (ARTAG) find AD comorbidity rates up to 40% for both [143] [144] [145] [146] [147] [148] [149] [150] . The classical conditions in this group, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick's disease, are much less prevalent, although PSP may be considerably more common than previously realized due to low clinical sensitivity for the diagnosis [143, [151] [152] [153] [154] [155] [156] [157] [158] .
Effective clinical trials depend on accurate estimates of required subject numbers and variability as well as effect size of the treatment. Increased variability of clinical decline rates will require larger subject numbers to overcome. Effect size depends on the efficacy of the therapeutic agent, which may be at least in part dependent on a matching of molecular mechanisms of agent and pathogenesis. Neuropathological comorbidities in AD affect rates of cognitive decline and are by definition different in their molecular pathogenesis from AD. Comorbidities are thus likely to lead to lower probability of clinical trial success. Stratifying AD subjects by presence and types of accompanying comorbidities might result in increased observed effect sizes in some groups as compared to others, potentially "rescuing" failed clinical trials. Accurate in-vivo diagnostic methods are urgently needed for the major AD comorbidities. Table 1 . NACC autopsy data, by decade, for basic AD-related neuropathological variables in 1,839 dementia cases with intermediate or high ADNC. Number of cases, means and medians are shown. NPTHAL = Thal amyloid phase; NPBRAAK = Braak neurofibrillary stage; NPNEUR = CERAD neuritic plaque density; NPDIFF = diffuse plaque density; NPAMY = cerebral amyloid angiopathy density; NPADNC = NIA-AA AD Neuropathological Change level. Decadal groups are significantly different (p < 0.000001 for all AD lesion types except NPDIFF (p = 0.00046) and NPAMY (p = 0.0126). 
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